Teijin Receives Additional Approval in Japan for Merz’s Xeomin® Botulinum Toxin Type A
FRANKFURT, Germany--(BUSINESS WIRE)--Merz Therapeutics, a business of the Merz Group and a leader in the…
5 years ago
TYAN to Bring AI and HPC Optimized Server Platforms at ISC 2021
TAIPEI, Taiwan--(BUSINESS WIRE)--#AI--TYAN®, an industry-leading server platform design manufacturer and a MiTAC Computing Technology Corporation…
5 years ago
China Dongxiang Announces Annual Results FY2020/2021?Revenue Increases by 27.8% to RMB1,970 Million
Direct Franchised Reform Bears Fruit Overall Business Achieved Healthy and Stable Development Results Highlights (RMB…
5 years ago
Poxel and Sumitomo Dainippon Pharma Announce the Approval of TWYMEEG® (Imeglimin hydrochloride) for the Treatment of Type 2 Diabetes in Japan
TWYMEEG® is a first-in-class drug with a unique dual mechanism of action for the treatment…
5 years ago
Cognite Data Fusion™ Receives MM Research Institute Award in ‘Smart Solutions: Digital Twin’ Category
TOKYO--(BUSINESS WIRE)--#data--Cognite, a global leader in industrial software innovation, today announced that Cognite Data Fusion™…
5 years ago
Toyoda Gosei Switches to Renewable Energy Sources at Three Locations in Japan
Part of company’s efforts to achieve carbon neutrality KIYOSU, Japan--(BUSINESS WIRE)--Toyoda Gosei Co., Ltd. (TOKYO:7282)…
5 years ago
CG Spectrum Becomes First Online Unreal Academic Partner
School partners with Epic Games to offer game development training using Unreal Engine MELBOURNE, Australia--(BUSINESS…
5 years ago
MODA MODA Utilizing Natural Ingredients to Prove Its Hair-Dyeing Effect on Kickstarter
- Presenting an unconventional product developed by a chemist from MIT - Darkening gray hair…
5 years ago
Trend Micro Vision One Stops Threats Faster, Streamlines Operations and Cuts Costs
Customers have experienced 79% savings when consolidating vendors with an extended detection and response solution…
5 years ago
China NMPA Approves Tislelizumab in Non-Small Cell Lung Cancer and Hepatocellular Carcinoma
Tislelizumab is approved for the first-line treatment of advanced non-squamous non-small cell lung cancer following…
5 years ago